SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-21-302652
Filing Date
2021-10-20
Accepted
2021-10-20 09:11:03
Documents
12
Period of Report
2021-10-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K AMENDMENT NO 1 d119375d8ka.htm   iXBRL 8-K/A 23556
  Complete submission text file 0001193125-21-302652.txt   150354

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aeri-20211015.xsd EX-101.SCH 2901
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeri-20211015_lab.xml EX-101.LAB 18852
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeri-20211015_pre.xml EX-101.PRE 11854
5 EXTRACTED XBRL INSTANCE DOCUMENT d119375d8ka_htm.xml XML 4147
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36152 | Film No.: 211332890
SIC: 2836 Biological Products, (No Diagnostic Substances)